IL‑32 promotes breast cancer cell growth and invasiveness

Wang,Shouman; Chen,Feiyu; Tang,Lili

doi:10.3892/ol.2014.2641

IL‑32 promotes breast cancer cell growth and invasiveness

Authors:
- Shouman Wang
- Feiyu Chen
- Lili Tang
View Affiliations

Affiliations: Department of Breast Surgery, Xiangya Hospital, Central South University, Changsha, Hunan 410008, P.R. China
Published online on: October 27, 2014 https://doi.org/10.3892/ol.2014.2641
Pages: 305-307

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Interleukin (IL)‑32 is a newly identified cytokine in humans and primates. It has been established that IL‑32 may antagonize cancer growth. However, to the best of our knowledge, the direct effect of IL‑32 on breast cancer cell growth has not yet been investigated. In addition, rodents lack the expression of IL‑32; hence, the effects of IL‑32 on breast cancer xenografts in nude mice have not been studied. The present study aimed to examine the potential regulatory effects of IL‑32 on breast cancer cells in nude mice. The effects of IL-32 on tumor cell growth in cell cuture and a tumor xenograft model were investigated, as well as the effects of IL-32 on apoptosis. The effects of IL‑32 on cell proliferation and apoptosis were investigated by MTT assay and TUNEL staining, respectively. The results revealed that IL‑32 increases the proliferation rate of cancer cells and decreases the rate of apoptosis, In addition, IL‑32 was found to enhance the growth of tumor xenografts in vivo. In summary, IL‑32 may represent a useful therapeutic target for human breast cancer.

View Figures

View References

1	Gelao L, Criscitiello C, Fumagalli L, et al: Tumour dormancy and clinical implications in breast cancer. E cancer medical science. 7:3202013.
2	Ligibel JA and Strickler HD: Obesity and its impact on breast cancer: tumor incidence, recurrence, survival, and possible interventions. Am Soc Clin Oncol Educ Book. 2013:52–59. 2013. View Article : Google Scholar
3	Cooney MA, Culleton-Quinn E and Stokes E: Current knowledge of pain after breast cancer treatment: a systematic review. Pain Manag Nurs. 14:110–123. 2013. View Article : Google Scholar : PubMed/NCBI
4	Makarem N, Chandran U, Bandera EV and Parekh N: Dietary fat in breast cancer survival. Annu Rev Nutr. 33:319–348. 2013. View Article : Google Scholar : PubMed/NCBI
5	Despas F, Roche H and Laurent G: Anticancer drug adherence. Bull Cancer. 100:473–484. 2013.(In French). PubMed/NCBI
6	Khan KH, Yap TA, Yan L and Cunningham D: Targeting the PI3K-AKT-mTOR signaling network in cancer. Chin J Cancer. 32:253–265. 2013. View Article : Google Scholar : PubMed/NCBI
7	Ma X, Liu L, Nie W, et al: Prognostic role of caveolin in breast cancer: a meta-analysis. Breast. 22:462–469. 2013. View Article : Google Scholar : PubMed/NCBI
8	Corben AD: Pathology of invasive breast disease. Surg Clin North Am. 93:363–392. 2013. View Article : Google Scholar : PubMed/NCBI
9	Chen WX, Hu Q, Qiu MT, et al: miR-221/222: promising biomarkers for breast cancer. Tumour Biol. 34:1361–1370. 2013. View Article : Google Scholar : PubMed/NCBI
10	O’Toole SA, Beith JM, Millar EK, et al: Therapeutic targets in triple negative breast cancer. J Clin Pathol. 66:530–542. 2013. View Article : Google Scholar
11	Zhang X, Li XR and Zhang J: Current status and future perspectives of PI3K and mTOR inhibitor as anticancer drugs in breast cancer. Curr Cancer Drug Targets. 13:175–187. 2013. View Article : Google Scholar
12	Warin R, Xiao D, Arlotti JA, Bommareddy A and Singh SV: Inhibition of human breast cancer xenograft growth by cruciferous vegetable constituent benzyl isothiocyanate. Mol Carcinog. 49:500–507. 2010. View Article : Google Scholar : PubMed/NCBI
13	Heinhuis B, Netea MG, van den Berg WB, Dinarello CA and Joosten LA: Interleukin-32: a predominantly intracellular proinflammatory mediator that controls cell activation and cell death. Cytokine. 60:321–327. 2012. View Article : Google Scholar : PubMed/NCBI
14	Soyka MB, Treis A, Eiwegger T, et al: Regulation and expression of IL-32 in chronic rhinosinusitis. Allergy. 67:790–798. 2012. View Article : Google Scholar : PubMed/NCBI
15	Meyer N, Christoph J, Makrinioti H, et al: Inhibition of angiogenesis by IL-32: possible role in asthma. J Allergy Clin Immunol. 129:964–973.e7. 2012. View Article : Google Scholar : PubMed/NCBI
16	Moldenhauer A, Futschik M, Lu H, et al: Interleukin 32 promotes hematopoietic progenitor expansion and attenuates bone marrow cytotoxicity. Eur J Immunol. 41:1774–1786. 2011. View Article : Google Scholar : PubMed/NCBI
17	Oh JH, Cho MC, Kim JH, et al: IL-32gamma inhibits cancer cell growth through inactivation of NF-kappaB and STAT3 signals. Oncogene. 30:3345–33598. 2011. View Article : Google Scholar : PubMed/NCBI
18	Felaco P, Castellani ML, De Lutiis MA, et al: IL-32: a newly-discovered proinflammatory cytokine. J Biol Regul Homeost Agents. 23:141–147. 2009.PubMed/NCBI
19	Nishida A, Andoh A, Inatomi O and Fujiyama Y: Interleukin-32 expression in the pancreas. J Biol Chem. 284:17868–178766. 2009. View Article : Google Scholar : PubMed/NCBI